• Traitements

  • Traitements systémiques : applications cliniques

  • Colon-rectum

Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer

Mené sur 78 patients atteints d'un cancer colorectal métastatique HER2+, cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du trastuzumab déruxtécan (un conjugué anticorps-médicament anti-HER2)

Biomarker-directed therapy is increasingly being used to treat metastatic colorectalcancer, including using RAS mutational status to select patients for EGFR antibodies use, mismatch repair deficiencyto select patients for treatment with PD-1 and CTLA-4 antibodies, and, more recently, BRAF mutational status to select for treatment with encorafenib plus cetuximab.

The Lancet Oncology , commentaire, 2020

Voir le bulletin